Limited coverage criteria – propranolol hydrochloride

Last updated on March 21, 2025

 

Return to Special Authority drug list 

Generic name

propranolol hydrochloride         

Strength & form

3.75 mg/mL oral solution

Special Authority criteria

Approval period

Initial

For the treatment of proliferating infantile1 hemangioma requiring systemic therapy when:

Patient has life- or function-threatening hemangioma

OR

Patient has ulcerated hemangioma with pain or a lack of response to wound-care measures

OR
 

Patient’s hemangioma presents a risk of permanent scarring or disfigurement

6 months

Renewal 

For the continued treatment of proliferating infantile hemangioma, when the patient has had an incomplete2 response to a 6-month course of treatment with propranolol oral solution

6 months3 

Special notes

  • 1PharmaCare considers coverage of infants for initial coverage up to 5 months of age. The age for treatment initiation will be corrected in cases of prematurity
  • 2The prescriber must provide details of the patient’s response versus pre-treatment baseline
  • 3PharmaCare provides a maximum of 2 years total coverage

Practitioner exemptions

  • No practitioner exemptions

Special Authority request form(s)